This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MarketVIEW: Candida Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Candida vaccines

http://www.reportlinker.com/p0961701/MarketVIEW-Candida-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Candida yeasts cause Candidiasis which is a fungal infection commonly found in humans. Infections can occur in the female Genital area "vulvovaginal candidiasis" of which nearly 75% of all adult women have had one "yeast infection" in their lifetime. Some women experience recurrent episodes (RVVC) which can cause considerable inconvenience and distress. Invasive Candidiasis, is a life threatening infection which mainly affects individuals with serious underlying co-morbidities. Infections usually occur in the hospital intensive care unit (ICU) where it is the fourth most common bloodstream infection (CDC Figures). 

This MarketVIEW This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Candida vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates for both Recurrent Vulvovaginal Candidiasis (RVVC) and invasive Candidiasis (in the ICU setting) indications. For RVVC indication 3 prevalence scenarios (LO/MID/HI) are included. The product also includes an up-to-date review of latest competitor activity in the field and Candida epidemiology. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Executive SummaryRVVC TX vaccine: available market ($000s) to 2030, realistic RVVCprevalenceRVVC TX vaccine: available market ($000s) to 2030 by conservative,realistic and optimistic RVVC prevalenceRVVC TX vaccine: available market (000s doses) to 2030Candida ICU PX vaccine: available market ($000s) to 2030Candida ICU PX vaccine: available market (000s doses) to 2030The role of Candida vaccinesCandida ICU PX vaccine: target product profileRVVC TX vaccine: target product profileCandida ICU PX vaccine: model assumptionsRVVC TX vaccine: model assumptionsKey commercial model assumptionsPricingCompetitor landscape: overviewPevion (PEV7)NovaDigm Therapeutics (NDV-3)Vulvovaginal candidiasis: overviewVulvovaginal candidiasis: surveillanceVulvovaginal candidiasis: regional dataVulvovaginal candidiasis: primary care consultationsVulvovaginal candidiasis: drug utilizationVulvovaginal candidiasis: drug utilizationVulvovaginal candidiasis: population based studiesVulvovaginal candidiasis: incidence/prevalence summaryInvasive candidiasis: overviewInvasive candidiasis: national surveillance dataInvasive candidiasis: estimating ICU admissionsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: 50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs